Letters Bias related to funding source in statin trials

No evidence of industry sponsorship bias in statin trials

BMJ 2014; 349 doi: http://dx.doi.org/10.1136/bmj.g6579 (Published 04 November 2014) Cite this as: BMJ 2014;349:g6579
  1. Huseyin Naci, research fellow1,
  2. Sofia Dias, research fellow2,
  3. Tony Ades, professor2
  1. 1LSE Health, London School of Economics and Political Science, London, UK
  2. 2School of Social and Community Medicine, University of Bristol, Bristol, UK
  1. h.naci{at}lse.ac.uk

We share many of Bero’s concerns regarding the industry sponsorship of research.1 2 3

Studies of industry sponsorship bias must take account of real differences between products and doses. We have shown previously that higher dose statins achieve greater cholesterol reductions from baseline than lower dose ones.4

Taking account of dose differences, and thereby comparing like …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe